《滬深兩市》滬綜深成半日各升逾0.5% 聯通漲停 生物製藥股造好
內地昨日(2日)新增4,804宗本土新冠確診個案。人行今日(3日)進行500億元人民幣(下同)7天期逆回購操作。人民幣兌美元中間價今上調171點。至於去年12月財新中國製造業採購經理指數(PMI)錄得49,較預期49.3低,並較11月指數低0.4個百分點,降至近三個月來最低。A股三大指數微微低開後倒升,半日升0.03%至0.56%。
上證綜指3,100點關失而復得,半日升17點或0.56%,報3,106點,成交額1,908.5億元;深證成指升60點或0.55%,報11,076點,成交額2,764億元;創業板指升不足1點或0.03%,報2,347點,成交額890億元。
中資金融股工行(601398.SH)跌0.7%,建行(601939.SH)跌0.4%。
汽車股寧德時代(300750.SZ)跌1.5%。比亞迪(002594.SZ)升1.2%。廣汽集團(601238.SH)升0.4%。
通訊服務板塊強勢,中國聯通(600050.SH)漲停。中國移動(600941.SH)升6.3%。中國電信(601728.SH)升5.3%。
科興制藥(688136.SH)升5.2%,其全資子公司深圳科興的新冠小分子口服藥SHEN26膠囊II期臨床研究成功完成全部受試者入組。另研究顯示SHEN26膠囊可以縮短輕症、普通型新型冠狀病毒感染患者的核酸轉陰時間,且安全性良好。
生物製藥股造好,康芝藥業(300086.SZ)漲停,公司指蒙脫石散產品整體訂單量很大,正加班加點趕工。仟源醫藥(300254.SZ)亦告漲停。內媒報道指蒙脫石散熱銷,多家藥店售罄及斷貨。在網購平台搜索發現,線上配送也處於斷貨狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.